APP and Alzheimer disease: We conclude that these anti-Abeta antagonists are capable of preventing and reversing established memory deficits in both sexes in aged transgenic AD mouse models following systemic long-term administration, and represent therapeutic disease-modifying candidates for Alzheimer's disease.